Verdict
Annalise.ai is one of the most ambitious AI radiology platforms in the world — its differentiator is breadth. While most FDA-cleared AI imaging tools target one or two specific findings (Viz.ai for stroke, Aidoc for multiple modules separately), Annalise covers 124+ chest X-ray findings and 130+ CT brain findings in single comprehensive products. Founded in Sydney, Australia (Annalise.ai is part of Harrison.ai), the platform is widely deployed in Australia, the UK, and several European markets, with growing US presence following FDA clearance milestones.
For health systems wanting a comprehensive AI safety net across high-volume imaging modalities, Annalise is the strongest single platform in the multi-finding category. For systems prioritising specific stroke-care or specialty workflows, Viz.ai (stroke) or Aidoc (foundation-model breadth) may be better fit. Many large health systems run multiple platforms for complementary coverage.
What Annalise.ai actually does
Two flagship products as of 2026:
- Annalise CXR: AI for chest X-ray covering 124+ findings (pneumothorax, pneumonia, pleural effusion, lung nodules, fractures, support-device positioning, and many more). Findings are flagged with confidence levels and presented in the radiologist\'s reading worklist via PACS integration.
- Annalise CTB (CT Brain): AI for non-contrast CT brain covering 130+ findings (intracranial haemorrhage, mass effect, hydrocephalus, midline shift, ischaemic changes, and many more).
Both products operate as decision-support / triage tools, not as autonomous diagnostic systems. The radiologist remains responsible for final interpretation; Annalise surfaces findings for review and prioritisation.
Regulatory status
- FDA: Annalise has FDA 510(k) clearances for specific findings on its chest X-ray product, with additional clearances continuing to roll out. Not all 124 findings are FDA-cleared in the US — clinically deployed configurations vary by region.
- TGA (Australia): Annalise.ai is approved by the Therapeutic Goods Administration with broader configuration than the US.
- UK MHRA / EU MDR: Approved in the UK and several EU markets under MDR / MHRA frameworks. The EU MDR transition has affected approval timelines for several AI imaging vendors industry-wide.
Strengths
- Breadth. 124+ chest X-ray findings and 130+ CT brain findings is materially broader than most FDA-cleared competitors. Acts as a "comprehensive safety net" for radiologists who don\'t want to miss subtle findings.
- Australian and UK clinical-validation evidence. Annalise has published peer-reviewed evidence on its products including studies in respected radiology journals. The TGA-approved configurations have been deployed at scale in Australian hospitals for years.
- Reduces missed-finding rates. Published evidence (and customer-reported case studies) suggests Annalise reduces missed findings — particularly subtle pneumothorax, small lung nodules, and incidental findings that are easy to overlook in high-volume reading.
- Strong PACS integration. Works with major PACS vendors and integrates into the radiologist\'s reading workflow rather than requiring a separate viewer.
- Vendor-neutral imaging: works across imaging-equipment vendors (GE, Siemens, Philips, Canon).
Weaknesses
- FDA coverage is narrower than Australian / UK approval. US deployments have access to a subset of the full Annalise feature set. The gap closes as additional FDA clearances roll out, but US health systems should verify which specific findings are FDA-cleared before signing.
- Two products, not many products. Annalise is heavily focused on chest X-ray and CT brain. Other modalities (musculoskeletal X-ray, mammography, abdominal CT) are not currently covered with the same depth. For comprehensive multi-modality AI, Aidoc has broader product coverage.
- Higher false-positive rate is a known characteristic of comprehensive multi-finding AI. When the AI is looking for 124+ findings simultaneously, false-positive rates per finding are non-zero — radiologists need workflow discipline to dismiss irrelevant flags efficiently. This is true of all comprehensive AI platforms, not Annalise-specific.
- Less brand recognition in the US. US radiologists are more familiar with Aidoc and Viz.ai. Annalise brand recognition has grown but lags. For US health systems, the procurement / IT engagement is a longer first-time experience than with established US vendors.
- Pricing not public. Enterprise contracts vary by hospital size, modality coverage, and finding set. Quotes via Annalise.ai sales.
Annalise.ai vs Aidoc vs Viz.ai
- Annalise.ai — broad multi-finding coverage on chest X-ray and CT brain (124+ and 130+ findings respectively). Best for "comprehensive safety net" use cases.
- Aidoc — multi-modality AI radiology with the 2026 foundation-model FDA clearance as a recent differentiator. Broader modality coverage than Annalise; slightly fewer per-modality findings.
- Viz.ai — stroke-care-workflow-first with the ConnectMobile team-coordination layer. Specific to stroke and a few other findings; less of a "general" AI radiology platform.
Many large health systems run multiple platforms for complementary coverage — Annalise for comprehensive chest X-ray + brain CT, Aidoc for breadth across other modalities, Viz.ai for stroke-care workflow specifically.
Bottom line
Annalise.ai is the strongest choice when comprehensive multi-finding AI on chest X-ray and CT brain is the priority — the breadth-of-coverage differentiator is real and the Australian / UK / EU clinical-validation evidence is solid. US health systems should verify which specific findings are FDA-cleared in their deployment configuration before signing. For broader modality coverage or US-specific brand familiarity, Aidoc is a reasonable alternative. For stroke-specific workflows, Viz.ai remains the leader.